Jim Neal, XOMA's Chief Executive Officer and member of the Board, joined the company in 2009. Mr. Neal brings more than 25 years' experience in forming and maximizing business and technology collaborations globally and in bringing novel products and technologies to market. Prior to XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos, Inc., a leading biosimulation company that acquired Iconix Biosciences, a privately held company where Mr. Neal was Chief Executive Officer. At Iconix, Mr. Neal established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs, Eli Lilly and the U.S. Food and Drug Administration. From, 1999-2002, he was Executive Vice President of Incyte Genomics, leading the global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis and Schering-Plough, as well as sales, marketing and business development activities for the company. Earlier, he was associated with Monsanto Company in positions of increasing responsibility. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an Executive MBA degree from Washington University in St. Louis, Missouri.
Tom Burns, Vice President, Finance and Chief Financial Officer, joined XOMA in August 2006 and has held various senior finance and accounting roles. He is responsible for all financial matters affecting or involving the XOMA companies, including directing XOMA's financial strategy, accounting, budgeting, financial planning and analysis and investor relations functions. Mr. Burns has 20 years of experience in accounting and finance in both biotechnology and high technology companies. Prior to XOMA, he held multiple senior financial management positions at high-tech companies including Mattson Technology, IntruVert Networks (acquired by McAfee), Niku Corporation (acquired by Computer Associates) and Conner Technology. Mr. Burns received his Bachelor's degree from Santa Clara University and his Masters of Business Administration from Golden Gate University.
Allan Gordon, MD, PhD, is XOMA's Vice President, Clinical. Dr. Gordon joined XOMA in 2014 to lead XOMA 358's clinical development activities, including designing, implementing, operating, analyzing and communicating results of clinical trials. Prior to joining XOMA, he was Senior Vice President, Clinical Development at Reservlogix where he led the clinical development function from 2008 to 2014, which included organizing and directing all clinical activities involving its lead compound. In addition, Allan served as CEO at Nile Therapeutics Inc. and as Senior Director, Clinical Research at Scios, where he led several clinical project teams in different regions and was responsible for development of nesiritide outside the US. From 2000 to 2003, Dr. Gordon was the Medical Director for Scandinavia at Bristol-Myers Squibb and also has served as consulting research physician or medical advisor to companies such as Astra-Zeneca and Novartis. Dr. Gordon earned MD and PhD degrees from the Karolinska Institute in Sweden where he also is Associate Professor in Cardiology. Dr. Gordon is Specialist in the fields of Internal Medicine, Cardiology, and Pharmaceutical Medicine.
Kirk Johnson, PhD, is XOMA's Vice President of Development. Dr. Johnson joined XOMA in 2013 to lead the Company's endocrine development programs. Prior to XOMA, Dr. Johnson was Chief Scientific Officer at Medicinova, following its merger with Avigen Inc. As an officer and V.P. Research & Development at Avigen, Dr. Johnson helped redirect the company from a gene therapy platform to one focused on neurologic pharmaceutical development. Earlier in his career, Dr. Johnson worked at Genesoft Pharmaceuticals and Chiron Corp (Novartis), where he focused on both protein and small molecule therapeutic research and development activities. Dr. Johnson earned a PhD in pharmacology and toxicology from the Medical College of Virginia and completed postdoctoral fellowships studying the mechanism of action of IL-2 at Dartmouth Medical School and University of California Berkeley wherein his discoveries included the STY class of kinases. He has authored over 80 published manuscripts and holds at least a dozen issued patents.